RESUMO

Chronic Obstructive Pulmonary Disease (COPD) is a preventable and treatable disease characterized mainly by pulmonary airflow limitation that is not fully reversible. New different pharmacological approaches to decrease inflammation of the airways and consequently disease progression and increase airway obstruction reversibility have been developed. In the present article, we review the new patents on phosphoinositide 3 kinase and NFκb inhibitors for future therapies.

Assuntos

Anti-Inflamatórios/uso terapêutico , Imidazolinas/uso terapêutico , NF-kappa B/antagonistas & inibidores , Inibidores de Fosfoinositídeo-3 Quinase , Doença Pulmonar Obstrutiva Crônica/tratamento farmacológico , Esteroides/uso terapêutico , Animais , Anti-Inflamatórios/farmacologia , Humanos , Imidazolinas/farmacologia , Patentes como Assunto , Esteroides/farmacologia , Serina-Treonina Quinases TOR/antagonistas & inibidores